Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | USP5 | P45974 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5080184 | 0.88 | HDAC3 (0.55) | NR4A2CES2CES1RAB9ALMNA | |
| SCHEMBL29399457 | 0.87 | NR4A2 (0.46) | NR4A2CES2CES1ALDH1A1CYP2C19 | |
| SCHEMBL22097301 | 0.87 | KMT2A (0.55) | NR4A2CES2CES1ALDH1A1CYP2C19 | |
| SCHEMBL28629610 | 0.87 | NR4A2 (0.46) | NR4A2CES2CES1ALDH1A1CYP2C19 | |
| SCHEMBL30416829 | 0.82 | ALDH1A1 (0.55) | NR4A2ALDH1A1CYP2C19KMT2ACYP1A2 | |
| SCHEMBL20703168 | 0.81 | CES2 (0.52) | NR4A2CES2CES1ALDH1A1CYP2C19 | |
| SCHEMBL2691520 | 0.80 | NR4A2 (0.62) | NR4A2CES2CES1ALDH1A1CYP2C19 | |
| SCHEMBL7220761 | 0.80 | CES1 (0.52) | CES2CES1KMT2ARAB9ALMNA | |
| SCHEMBL31413025 | 0.79 | CES2 (0.46) | NR4A2CES2CES1RAB9AHCAR1 | |
| SCHEMBL31585604 | 0.79 | HCAR2 (0.61) | NR4A2ALDH1A1CYP2C19GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| EP-1745004-B1 | ARYL KETONE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2016-05-18 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-9035085-B2 | Aryl ketone compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | claimed |
| US-20080167217-A1 | aryl ketone compounds and compositions containing them which facilitate the delivery of active agents. The aryl ketone compounds have the formula** Image-1or a salt thereof, where n=1 to 9, and R1 to R5 are independently hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, C2 to C4 alkenyl, halogen, hydroxyl, | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-07-10 | — | — | US | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | disclosed |
| US-11685740-B2 | Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2023-06-27 | — | — | US | disclosed |
| CN-110072862-B | Bicyclic nitrogen-containing heterocyclic derivative and pharmaceutical composition containing the same | 盐野义制药株式会社 | 2022-05-13 | — | — | CN | disclosed |
| US-20210317125-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2021-10-14 | — | — | US | disclosed |
| US-11066409-B2 | Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2021-07-20 | — | — | US | disclosed |
| US-20200048257-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2020-02-13 | — | — | US | disclosed |
| US-20090131384-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | SYNDEXA PHARMACEUTICALS CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131384-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | SYNDEXA PHARMACEUTICALS CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| US-20080255250-A1 | Compounds and Compositions for Delivering Active Agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255250-A1 | Compounds and Compositions for Delivering Active Agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080167217-A1 | aryl ketone compounds and compositions containing them which facilitate the delivery of active agents. The aryl ketone compounds have the formula** Image-1or a salt thereof, where n=1 to 9, and R1 to R5 are independently hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, C2 to C4 alkenyl, halogen, hydroxyl, | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167217-A1 | aryl ketone compounds and compositions containing them which facilitate the delivery of active agents. The aryl ketone compounds have the formula** Image-1or a salt thereof, where n=1 to 9, and R1 to R5 are independently hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, C2 to C4 alkenyl, halogen, hydroxyl, | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2007111994-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | SYNDEXA PHARMACEUTICALS CORPORATION (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131384-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | NR1H3, NR1H2, SREBF1 | NR4A2 395/4885CES2 918/4885CES1 81/4885 |
| US-20200048257-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | P2RX7, P2RX2, P2RX5 | NR4A2 228/4885CES2 3124/4885CES1 3804/4885 |
| US-11685740-B2 | Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same | P2RX7, P2RX2, P2RX1 | NR4A2 172/4885CES2 1859/4885CES1 1677/4885 |
| US-11066409-B2 | Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same | P2RX7, P2RX2, P2RX5 | NR4A2 228/4885CES2 3124/4885CES1 3804/4885 |
| US-20210317125-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | P2RX7, P2RX2, P2RX1 | NR4A2 172/4885CES2 1859/4885CES1 1677/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | NR4A2 3782/4885CES2 3438/4885CES1 3038/4885 |
| US-20080255250-A1 | Compounds and Compositions for Delivering Active Agents | SERPINB1, ELANE, MMP8 | NR4A2 3277/4885CES2 55/4885CES1 490/4885 |
| US-20080167217-A1 | aryl ketone compounds and compositions containing them which facilitate the delivery of active agents. The aryl ketone compounds have the formula** Image-1or a salt thereof, where n=1 to 9, and R1 to R5 are independently hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, C2 to C4 alkenyl, halogen, hydroxyl, | AKR1C3, AKR1C1, AKR1A1 | NR4A2 738/4885CES2 537/4885CES1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.